Key result
In animal models, CAS 1609 acted as a potent, long-lasting orally active nitric oxide donor that improved haemodynamics and reduced mortality by 80% in dogs with acute heart failure.
Why the study?
Does the novel nitric oxide donor CAS 1609 improve haemodynamics and reduce mortality in animal models of acute heart failure?
Population
In vitro guinea-pig pulmonary artery strips, anaesthetized pigs, anaesthetized dogs, anaesthetized dogs with…
Design
Preclinical
Follow-up
5 days (in conscious dogs)
Authors
Loading...
May warrant preclinical development of oral NO donors; leaves open translation to human acute HF trials.
Does the novel nitric oxide donor CAS 1609 improve haemodynamics and reduce mortality in animal models of acute heart failure?
CAS 1609 is a potent, orally active nitric oxide donor that improves haemodynamics and reduces mortality in a canine model of acute heart failure without developing tolerance over 5 days of administration.
Bohn et al. (1995) studied Animal models (guinea-pigs, pigs, dogs). CAS 1609 was evaluated on Haemodynamic effects and mortality. In animal models, CAS 1609 acted as a potent, long-lasting orally active nitric oxide donor that improved haemodynamics and reduced mortality by 80% in dogs with acute heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: